DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xvfsmp/birch_pollen) has announced the addition of the "Birch Pollen Allergy - Pipeline Review, H1 2013" report to their offering.
'Birch Pollen Allergy - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Birch Pollen Allergy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Birch Pollen Allergy.
Scope
- A snapshot of the global therapeutic scenario for Birch Pollen Allergy.
- A review of the Birch Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Birch Pollen Allergy pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Companies Involved in Birch Pollen Allergy Therapeutics Development
- ALK-Abello A/S
- Allergopharma Joachim Ganzer KG
- Circassia Holdings Ltd.
- ANERGIS SA
- Biomay AG
Drug Profiles
- Birch Pollen Allergoid
- AL-0206st
- ALK Birch Pollen Vaccine
- Recombinant Birch Pollen Allergen
- BM-31
- ToleroMune Birch Allergy T-Cell Vaccines
- AllerT
- PL-102
For more information visit http://www.researchandmarkets.com/research/xvfsmp/birch_pollen
